University Heart Grand OpeningZippity Doo Dah gives to BCHTomorrow. Every Day.The Manning Family Fund for a Healthier Mississippi
  • George W. Booz, PhD, FAHA

    BoozGeorgewebsmall.jpg

    Associate Professor
    Office: R499-03
    Phone: (601) 984-4401
    E-mail: GBooz@umc.edu

     
    View CV

    Research interests

    • Cardiac hypertrophy and remodeling
    • Heart failure
    • Stem cell-based cardiac repair

    Current research

    One area of research is focused on understanding the regulation of cytokine inflammatory signaling in the heart and the role of that signaling in cardiac remodeling, specifically left ventricular hypertrophy and heart failure. Two specific questions that the laboratory is currently addressing are whether the intensity and duration of IL-6-type cytokine signaling in cardiac muscle determines the character of the genetic response, and whether there is a difference in its regulation between cardiac muscle and cardiac blood vessels (endothelial cells).

    My laboratory is also investigating ways to improve the therapeutic utility of hematopoietic stem cells for repairing the injured heart. Stem cell therapy represents an important advance in the prevention and treatment of heart failure due to ischemic heart disease or myocardial infarction. However, hematopoietic stem cell therapy is severely hampered by the poor survivability of these cells in the injured heart, which represents a hostile environment. We are interested in re-engineering hematopoietic stem cells to improve their survivability when placed in the damaged heart.

    Selected publications

    • Kurdi, M., Sivakumaran, V., Duhe, R. J., Aon, M. A., Paolocci, N., and Booz, G. W. (2012) Depletion of cellular glutathione modulates LIF-induced JAK1-STAT3 signaling in cardiac myocytes, The international journal of biochemistry & cell biology. PubMed article  
    • Zgheib, C., Kurdi, M., Zouein, F. A., Gunter, B. W., Stanley, B. A., Zgheib, J., Romero, D. G., King, S. B., Paolocci, N., and Booz, G. W. (2012) Acyloxy Nitroso Compounds Inhibit LIF Signaling in Endothelial Cells and Cardiac Myocytes: Evidence That STAT3 Signaling Is Redox-Sensitive, PloS one7, e43313. PubMed article  
    • Zouein, F. A., Zgheib, C., Liechty, K. W., and Booz, G. W. (2012) Post-Infarct Biomaterials, Left Ventricular Remodeling, and Heart Failure: Is Good Good Enough?, Congest Heart Fail. PubMed article  
    • Alturkmani, H. J., Zgheib, C., Zouein, F. A., Alshaaer, N. E., Kurdi, M., and Booz, G. W. (2012) Selenate enhances STAT3 transcriptional activity in endothelial cells: differential actions of selenate and selenite on LIF cytokine signaling and cell viability, Journal of inorganic biochemistry109, 9-15. PubMed article  
    • Smith, J. K., Patil, C. N., Patlolla, S., Gunter, B. W., Booz, G. W., and Duhe, R. J. (2012) Identification of a redox-sensitive switch within the JAK2 catalytic domain, Free radical biology & medicine52, 1101-1110. PubMed article 
    • Arany, I., Reed, D. K., Grifoni, S. C., Chandrashekar, K., Booz, G. W., and Juncos, L. A. (2012) A novel U-STAT3-dependent mechanism mediates the deleterious effects of chronic nicotine exposure on renal injury, American journal of physiology. Renal physiology302, F722-729. PubMed article  
    • Zgheib, C., Zouein, F. A., Chidiac, R., Kurdi, M., and Booz, G. W. (2012) Calyculin A reveals serine/threonine phosphatase protein phosphatase 1 as a regulatory nodal point in canonical signal transducer and activator of transcription 3 signaling of human microvascular endothelial cells, Journal of interferon & cytokine research32, 87-94. PubMed article 
    • Zgheib C, Zouein FA, Kurdi M, Booz GW. (2012) Differential STAT3 Signaling in the Heart: Impact of Concurrent Signals and Oxidative Stress. JAK-STAT. 1:102-111.
    • Kurdi, M., and Booz, G. W. (2011) Focus on mitochondria dysfunction and dysregulation in heart failure: towards new therapeutic strategies to improve heart function, Congest Heart Fail17, 255-256. PubMed article 
    • Zouein, F. A., Duhe, R. J., and Booz, G. W. (2011) JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth, Growth Factors29, 245-252. PubMed article 
    • Kurdi, M., and Booz, G. W. (2011) New take on the role of angiotensin II in cardiac hypertrophy and fibrosis, Hypertension57, 1034-1038. PubMed article 
    • Kurdi, M., and Booz, G. W. (2011) Three 4-letter words of hypertension-related cardiac hypertrophy: TRPC, mTOR, and HDAC, Journal of molecular and cellular cardiology50, 964-971. PubMed article 
    • Booz, G. W. (2011) Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress, Free radical biology & medicine51, 1054-1061. PubMed article 
    • Kurdi, M., and Booz, G. W. (2010) Deciphering STAT3 signaling in the heart: plasticity and vascular inflammation, Congest Heart Fail16, 234-238. PubMed article
    • Booz, G. W. (2010) Novel drugs targeting hypertension revisited, Journal of cardiovascular pharmacology56, 213-214. PubMed article
    • Kurdi, M., Chidiac, R., Hoemann, C., Zouein, F., Zgheib, C., and Booz, G. W. (2010) Hydrogels as a platform for stem cell delivery to the heart, Congest Heart Fail16, 132-135. PubMed article 
    • Booz GW. (2010) Oxidative Stress and Heart Failure: Still a Viable Therapeutic Target? In: García JE, Wright VR eds. Congestive Heart Failure: Symptoms, Causes and Treatment. Hauppauge, New York: Nova Science Publishers; pp. 89-109.
    • Kurdi, M., and Booz, G. W. (2009) JAK redux: a second look at the regulation and role of JAKs in the heart, American journal of physiology. Heart and circulatory physiology297, H1545-1556. PubMed article 
    • Kurdi, M., and Booz, G. W. (2008) Growing hearts by the bushel, Congest Heart Fail14, 95-96. PubMed article
    • Booz GW, Baker KM. (2008) Protein phosphorylation. In. Hypertension Primer: The Essentials of High Blood Pressure (4th ed), Senior Editors: J. L. Izzo and H. R. Black. Baltimore, Maryland: Lippincott Williams & Wilkins, pp. 16-21.
    • Kurdi, M., and Booz, G. W. (2007) G-CSF-based stem cell therapy for the heart--unresolved issues part B: Stem cells, engraftment, transdifferentiation, and bioengineering, Congest Heart Fail13, 347-351. PubMed article 
    • Kurdi, M., and Booz, G. W. (2007) Can the protective actions of JAK-STAT in the heart be exploited therapeutically? Parsing the regulation of interleukin-6-type cytokine signaling, Journal of cardiovascular pharmacology50, 126-141. PubMed article 
    • Kurdi, M., and Booz, G. W. (2007) G-CSF-based stem cell therapy for the heart-unresolved issues part A: paracrine actions, mobilization, and delivery, Congest Heart Fail13, 221-227. PubMed article  
    • Booz, G. W. (2007) Devising new drugs for the treatment of hypertension--"novel drugs targeting hypertension: renin inhibitors and beyond", Journal of cardiovascular pharmacology50, 1-2. PubMed article 
    • Booz, G. W. (2007) PARP inhibitors and heart failure--translational medicine caught in the act, Congest Heart Fail13, 105-112. PubMed article 
    • Booz, GW. (2007) Left ventricular physiology in hypertension. In: Comprehensive Hypertension. Editors: Y. H. Lip and J. E. Hall. Mosby, Chapter 10, pp.113-121.